Empagliflozin or dapagliflozin
Intervention1 paper5 findings
C · W · M · H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.
Company ties: findings with an author at a company, or from a paper that declares the maker’s interest.
- Human trial1
Outcomes
1Left ventricular ejection fraction
no changein humans1
1 study
Left ventricular ejection fraction
no changein humans1
Empagliflozin or dapagliflozin has no effect on left ventricular ejection fraction in humans.
Humanstype 2 diabetes mellitus; uncontrolled baseline-to-follow-up comparisonheart10 mg/day of either drugsix monthsn = 51
Cardiovascular, Renal, and Metabolic Effects of SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Prospective Cohort Study · Research Square · 7 Oct 2026 · Preprint
Associations
4Pulmonary artery systolic pressure
upin humans1
1 study
Pulmonary artery systolic pressure
upin humans1
Empagliflozin or dapagliflozin is associated with pulmonary artery systolic pressure in humans.
Humanstype 2 diabetes mellitus; remained within the normal physiological rangepulmonary artery10 mg/day of either drugsix monthsn = 51
Cardiovascular, Renal, and Metabolic Effects of SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Prospective Cohort Study · Research Square · 7 Oct 2026 · Preprint
Systolic blood pressure
downin humans1
1 study
Systolic blood pressure
downin humans1
Empagliflozin or dapagliflozin is associated with systolic blood pressure in humans.
Humanstype 2 diabetes mellitus; uncontrolled baseline-to-follow-up comparison10 mg/day of either drugsix monthsn = 51
Cardiovascular, Renal, and Metabolic Effects of SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Prospective Cohort Study · Research Square · 7 Oct 2026 · Preprint
Urinary albumin-to-creatinine ratio
downin humans1
1 study
Urinary albumin-to-creatinine ratio
downin humans1
Empagliflozin or dapagliflozin is associated with urinary albumin-to-creatinine ratio in humans.
Humanstype 2 diabetes mellitus; uncontrolled baseline-to-follow-up comparison10 mg/day of either drugsix monthsn = 51
Cardiovascular, Renal, and Metabolic Effects of SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Prospective Cohort Study · Research Square · 7 Oct 2026 · Preprint
HbA1c
downin humans1
1 study
HbA1c
downin humans1
Empagliflozin or dapagliflozin is associated with HbA1c in humans.
Humanstype 2 diabetes mellitus; uncontrolled baseline-to-follow-up comparison10 mg/day of either drugsix monthsn = 51
Cardiovascular, Renal, and Metabolic Effects of SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Prospective Cohort Study · Research Square · 7 Oct 2026 · Preprint